Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Baxter
Express Scripts
Boehringer Ingelheim
Harvard Business School
McKesson
Dow

Last Updated: December 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for GS-0976

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for GS-0976?

GS-0976 is an investigational drug.

There have been 6 clinical trials for GS-0976. The most recent clinical trial was a Phase 1 trial, which was initiated on August 1st 2016.

The most common disease conditions in clinical trials are Non-alcoholic Fatty Liver Disease, Fatty Liver, and Liver Diseases. The leading clinical trial sponsors are Gilead Sciences, Novo Nordisk A/S, and Nimbus Apollo.

There are three US patents protecting this investigational drug and sixty-one international patents.

Recent Clinical Trials for GS-0976
TitleSponsorPhase
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)Novo Nordisk A/SPhase 2
Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Adults With Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 2
Safety and Efficacy of Selonsertib, GS-0976, GS-9674, and Combinations in Participants With Bridging Fibrosis or Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)Gilead SciencesPhase 2

See all GS-0976 clinical trials

Clinical Trial Summary for GS-0976

Top disease conditions for GS-0976
Top clinical trial sponsors for GS-0976

See all GS-0976 clinical trials

US Patents for GS-0976

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
GS-0976   Start Trial Solid forms of a thienopyrimidinedione ACC inhibitor and methods for production thereof Gilead Apollo, LLC (Foster City, CA)   Start Trial
GS-0976   Start Trial ACC inhibitors and uses thereof Nimbus Apollo, Inc. (Cambridge, MA)   Start Trial
GS-0976   Start Trial ACC inhibitors and uses thereof Gilead Apollo, LLC (Foster City, CA)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for GS-0976

Drugname Country Document Number Estimated Expiration Related US Patent
GS-0976 Argentina 107790 2036-03-02   Start Trial
GS-0976 Australia 2017226267 2036-03-02   Start Trial
GS-0976 Brazil 112018067408 2036-03-02   Start Trial
GS-0976 Canada 3015526 2036-03-02   Start Trial
GS-0976 China 108699078 2036-03-02   Start Trial
GS-0976 Eurasian Patent Organization 201891692 2036-03-02   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKinsey
Colorcon
Express Scripts
Merck
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.